In experiments conducted on the renal carcinoma cell line 786-O, elacridar was used at concentrations of 2.5 μM and 5 μM in combination with sunitib, resulting in an enhanced cytotoxic effect through the inhibition of P-gp activity [61]. Here, PGP is linked to renal carcinoma.